Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT03601702
Recruiting Observational

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

NCT03601702 · tracked via the Priya Life Science Italy tracker
Sponsor
Niguarda Hospital
Phase
Observational
Started
2022-01-01
Last updated
2026-04-16

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

Mechanical thrombectomy with EmboTrap ® II Device

Mechanical thrombectomy with EmboTrap ® II Device: Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)

Study summary

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * Signed Informed Consent Form * Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1 * ASPECTS ≥ 6 * Mismatch or good collaterals showed at MR or multiphasic CTA or pCT * Groin Puncture performed within 12 hours from symptom onset * Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment Exclusion criteria * Informed consent not given * Extracranial or tandem occlusion

Primary outcome measure(s)

  • Safety: device -related haemorrhages rate showed by CT/MR — 10 days
    Procedure-related mortality rate
  • Efficacy: Restoration of cerebral blood flow at the end of the procedure — 1 day
    Restoration of cerebral blood flow

Trial sites (1)

FacilityCityRegionStatus
ASST GOM Niguarda Milan Italy Recruiting

More Niguarda Hospital trials in Italy

The PseAn Study - Study Protocol Recruiting
Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism Recruiting
MYTHS - MYocarditis THerapy With Steroids Recruiting
Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy Recruiting
Impact of Regional Anesthesia on Chronic Post-operative Pain Enrolling by invitation

Other trials for the same condition

NeVa ONE Registry Study Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function Recruiting
Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke Recruiting
EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03601702 on ClinicalTrials.gov ↗ ← All trials in Italy